Ihc to dd retroperitoneal carcinoma
Reading File
Finding Sources
Finding Sources
Searching the Web
IHC panel retroperitoneal carcinoma differential diagnosis immunohistochemistry markers
Finding Sources
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC5923363
Here is a comprehensive guide to IHC for differential diagnosis of retroperitoneal carcinoma.
IHC Panel for Retroperitoneal Carcinoma - Differential Diagnosis
Retroperitoneal masses encompass a wide range of tumor types. The diagnostic approach uses a stepwise IHC strategy.
Step 1: Establish Lineage (First-Line Panel)
Before determining the primary site, confirm whether the tumor is a carcinoma, sarcoma, lymphoma, or melanoma:
| Marker | Positive in |
|---|---|
| Pan-CK (AE1/AE3, CAM5.2) | Carcinoma, mesothelioma |
| CD45 (LCA) | Lymphoma |
| S100 / SOX10 | Melanoma, nerve sheath tumors |
| Vimentin | Sarcoma, RCC, adrenocortical |
| Desmin / SMA | Smooth/skeletal muscle sarcoma |
A vimentin-negative tumor is unlikely to be a sarcoma, lymphoma, or melanoma.
Step 2: CK7 / CK20 Profile - The Backbone of Carcinoma Subtyping
| Profile | Common Primary Sites |
|---|---|
| CK7+ / CK20- | Lung, breast, ovary, endometrium, thyroid, cervix, pancreas, biliary |
| CK7+ / CK20+ | Urothelial, pancreas, mucinous ovarian, gastric, cholangiocarcinoma |
| CK7- / CK20+ | Colorectal, Merkel cell |
| CK7- / CK20- | RCC, adrenocortical, HCC, prostate, squamous (some), mesothelioma |
Step 3: Organ-Specific IHC Markers for Retroperitoneal Tumors
Renal Cell Carcinoma (RCC)
The most common retroperitoneal primary carcinoma.
| Marker | Result | Notes |
|---|---|---|
| PAX8 | + | Highly sensitive for RCC; also + in thyroid, Mullerian |
| pVHL | + | Highly sensitive + specific for clear cell RCC |
| CD10 | + | Sensitive but not specific |
| RCC marker (RCCma) | + | Less sensitive in high-grade |
| CAIX (carbonic anhydrase IX) | + | Strong in clear cell RCC |
| CK7 | - (clear cell), + (papillary) | |
| CK20 | - | |
| Vimentin | + |
Panel recommended: PAX8 + pVHL + RCCma + CAIX. Single-marker approach discouraged.
Adrenocortical Carcinoma (ACC)
Critical mimic of RCC in the retroperitoneum.
| Marker | Result |
|---|---|
| Melan-A (A103) | + |
| Inhibin-alpha | + |
| SF-1 (steroidogenic factor-1) | + (most specific) |
| Synaptophysin | +/- |
| Pan-CK | - or focal |
| PAX8 | - |
| RCC marker | - |
| Chromogranin | - |
Key: Inhibin+ / PAX8- strongly favors ACC over RCC.
Retroperitoneal Germ Cell Tumor (GCT)
Common in young males as retroperitoneal primary.
| Marker | Result | Tumor type |
|---|---|---|
| PLAP | + | Seminoma / NSGCT |
| OCT4 (OCT3/4) | + | Seminoma, embryonal carcinoma |
| SALL4 | + | All GCTs (highly sensitive) |
| AFP | + | Yolk sac tumor |
| hCG / beta-hCG | + | Choriocarcinoma |
| CD30 | + | Embryonal carcinoma |
| D2-40 | + | Seminoma |
| Pan-CK | Variable (+ in embryonal, - in seminoma) |
Hepatocellular Carcinoma (HCC) - Retroperitoneal metastasis
| Marker | Result |
|---|---|
| Arginase-1 (ARG1) | + (most specific) |
| HepPar-1 (Hepar1) | + |
| Canalicular pCEA / CD10 / CD13 | + (canalicular pattern) |
| GPC3 (glypican-3) | + |
| AFP | + (less sensitive) |
| CK7 | - |
| CK20 | - |
| PAX8 | - |
Neuroendocrine Carcinoma (NEC) - including paraganglioma/pheo
| Marker | Result |
|---|---|
| Chromogranin A | + |
| Synaptophysin | + |
| CD56 | + |
| TTF1 | + (small cell lung origin) |
| Ki-67 | Used for grading (G1 <3%, G2 3-20%, G3 >20%) |
| GATA3 | + in paraganglioma |
| S100 (sustentacular cells) | + in paraganglioma |
| Pan-CK | + (carcinoma); - (paraganglioma) |
Paraganglioma: Chromogranin+ / Synaptophysin+ / CK- - distinguish from NEC which is CK+.
Mesothelioma (Peritoneal) - vs retroperitoneal adenocarcinoma
| Positive (Mesothelial) | Negative (Carcinoma favored) |
|---|---|
| Calretinin | MOC-31 |
| WT1 (nuclear) | Ber-EP4 |
| D2-40 (podoplanin) | BG-8 (Lewisy) |
| CK5/6 | B72.3 |
| Thrombomodulin | CA19-9 |
International Mesothelioma Interest Group recommends: 2 positive mesothelial markers + 2 negative (carcinoma) markers.
Retroperitoneal Liposarcoma (Sarcoma mimic)
| Marker | Result |
|---|---|
| MDM2 | + (amplified) |
| CDK4 | + |
| HMGA2 | + |
| Pan-CK | - |
| S100 | +/- (well-differentiated) |
MDM2/CDK4 co-amplification by FISH confirms dedifferentiated liposarcoma.
Quick-Reference Summary Table
| Tumor | Key Positive Markers | Key Negative Markers |
|---|---|---|
| RCC (clear cell) | PAX8, pVHL, CAIX, CD10, Vimentin | CK7, CK20, Inhibin |
| Adrenocortical Ca | Inhibin, Melan-A, SF-1, Synaptophysin | PAX8, Pan-CK, Chromogranin |
| Retroperitoneal GCT | SALL4, OCT4, PLAP, AFP/hCG (subtypes) | - |
| HCC (met) | ARG1, HepPar1, GPC3, canalicular CEA | CK7, CK20, PAX8 |
| NEC / Paraganglioma | Chromogranin, Synaptophysin, CD56 | CK (paraganglioma) |
| Peritoneal Mesothelioma | Calretinin, WT1, D2-40, CK5/6 | BerEP4, MOC-31, B72.3 |
| Liposarcoma | MDM2, CDK4, Vimentin | Pan-CK |
| Colorectal met | CK20, CDX2, SATB2 | CK7 |
| Ovarian serous | PAX8, WT1, ER, CA-125 | - |
| Urothelial Ca | GATA3, CK7, CK20, p63, uroplakin | - |
Practical Diagnostic Algorithm
Retroperitoneal mass on biopsy
|
v
Pan-CK + CD45 + S100/SOX10 + Vimentin
|
CK positive? --> CARCINOMA / MESOTHELIOMA
|
CK7 / CK20 profile
|
CK7-/CK20- --> RCC, ACC, HCC, Prostate, GCT
CK7+/CK20- --> Ovarian, Lung, Breast, Endometrial
CK7-/CK20+ --> Colorectal (CDX2, SATB2)
CK7+/CK20+ --> Urothelial, Mucinous ovarian, Pancreas
Key practical tips:
- In a young male: always include GCT markers (SALL4, OCT4, PLAP) first
- RCC vs ACC is a common pitfall: use PAX8 (RCC+, ACC-) and Inhibin (ACC+, RCC-)
- Paraganglioma vs NEC: CK separates them (NEC+, paraganglioma-)
- Always use a panel, never a single marker
This is a shared conversation. Sign in to Orris to start your own chat.